Skip to main content
SpringerLink
Log in

L’adiponectine : une adipokine aux multiples visages

  • Chapter
Physiologie et physiopathologie du tissu adipeux

  • 885 Accesses

Résumé

Le tissu adipeux (TA) est maintenant reconnu comme un organe sécrétoire majeur capable de synthétiser une large variété de facteurs, les adipokines (molécules synthétisées et secrétées par le TA et agissant localement sur un mode autocrine-paracrine, ou endocrine au niveau systémique), dont certaines modulent la sensibilité à l’insuline et l’équilibre énergétique [1, 2]. Ces adipokines exercent des effets physiologiques pléiotropes, et il est de plus en plus clair que leur déséquilibre participe à la genèse de nombreuses affections métaboliques et de leurs complications telles que le diabète et les affections cardiovasculaires. Le TA est un tissu hétérogène composé d’adipocytes et de nombreux autres types cellulaires (préadipocytes, fibroblastes, cellules endothéliales, macrophages et d’autres cellules du système immunitaire) constituant la fraction stroma-vasculaire (FSV). Certaines adipokines sont majoritairement produites par les adipocytes, tandis que d’autres sont préférentiellement sécrétées par les cellules de la FSV, et en particulier par les macrophages. Dans la suite de ce chapitre nous présenterons les propriétés d’une adipokine majoritairement produite par les adipocytes: l’adiponectine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Bastard JP, Maachi M, Lagathu C et al. (2006) Recent advances in the relationship between obesity, inflammation and insulin resistance. Eur Cytokine Netw 17: 4–12

    PubMed  CAS  Google Scholar 

  2. Antuna-Puente B, Fève B, Fellahi S, Bastard JP (2008) Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 34: 2–11

    Article  PubMed  CAS  Google Scholar 

  3. Scherer PE, Williams S, Fogliano M et al. (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746–9

    Article  PubMed  CAS  Google Scholar 

  4. Maeda K, Okubo K, Shimomura I et al. (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221: 286–9

    Article  PubMed  CAS  Google Scholar 

  5. Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697–703

    Article  PubMed  CAS  Google Scholar 

  6. Nakano Y, Tobe T, Choi-Miura NH et al. (1996) Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120: 803–12

    Article  PubMed  CAS  Google Scholar 

  7. Wang Y, Lam KS, Yau MH, Xu A (2008) Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 409: 623–33

    Article  PubMed  CAS  Google Scholar 

  8. Hoffstedt J, Arvidsson E, Sjolin E, et al. (2004) Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab 89: 1391–6

    Article  PubMed  CAS  Google Scholar 

  9. Halberg N, Schraw TD, Wang ZV et al. (2009) Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 58: 1961–70

    Article  PubMed  Google Scholar 

  10. Tietge UJ, Boker KH, Manns MP, Bahr MJ (2004) Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 287: E82–9

    Article  PubMed  CAS  Google Scholar 

  11. Von Eynatten M, Liu D, Hock C et al. (2009) Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes 58: 2093–9

    Article  Google Scholar 

  12. Stenvinkel P, Marchlewska A, Pecoits-Filho R et al. (2004) Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65: 274–81

    Article  PubMed  CAS  Google Scholar 

  13. Beige J, Heipmann K, Stumvoll M et al. (2009) Paradoxical role for adiponectin in chronic renal diseases? An example of reverse epidemiology. Expert Opin Ther Targets 13: 163–73

    Article  PubMed  CAS  Google Scholar 

  14. Möller KF, Dieterman C, Herich L et al. (2012) High serum adiponectin concentration in children with chronic kidney disease. Pediatr Nephrol 27: 243–9

    Article  PubMed  Google Scholar 

  15. Cui J, Panse S, Falkner B (2011) The role of adiponectin in metabolic and vascular disease: a review. Clin Nephrol 75: 26–33

    PubMed  CAS  Google Scholar 

  16. Yamauchi T, Kamon J, Ito Y et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762–9

    Article  PubMed  CAS  Google Scholar 

  17. Kadowaki T, Yamauchi T, Kubota N et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784–92

    Article  PubMed  CAS  Google Scholar 

  18. Yamauchi T, Nio Y, Maki T et al. (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13: 332–9

    Article  PubMed  CAS  Google Scholar 

  19. Hug C, Wang J, Ahmad NS et al. (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci États-Unis 101: 10308–13

    Article  CAS  Google Scholar 

  20. Arita Y, Kihara S, Ouchi N et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79–83

    Article  PubMed  CAS  Google Scholar 

  21. Staiger H, Tschritter O, Machann J et al. (2003) Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 11: 368–72

    Article  PubMed  CAS  Google Scholar 

  22. Cook JR, Semple RK (2010) Hypoadiponectinemia—cause or consequence of human “insulin resistance”? J Clin Endocrinol Metab 95: 1544–54

    Article  PubMed  CAS  Google Scholar 

  23. Yamauchi T, Kamon J, Waki H et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941–6

    Article  PubMed  CAS  Google Scholar 

  24. Tomas E, Tsao TS, Saha AK et al. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci États-Unis 99: 16309–13

    Article  CAS  Google Scholar 

  25. Yamauchi T, Kamon J, Minokoshi Y et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288–95

    Article  PubMed  CAS  Google Scholar 

  26. Mao X, Kikani CK, Riojas RA et al. (2006) APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8: 516–23

    Article  PubMed  CAS  Google Scholar 

  27. Wang C, Xin X, Xiang R et al. (2009) Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cell. J Biol Chem 284: 31608–15

    Article  PubMed  CAS  Google Scholar 

  28. Semple RK, Soos MA, Luan J et al. (2006) Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab 91: 3219–23

    Article  PubMed  CAS  Google Scholar 

  29. Semple RK, Cochran EK, Soos MA et al. (2008) Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care 31: 977–9

    Article  PubMed  CAS  Google Scholar 

  30. Antuna-Puente B, Boutet E, Vigouroux C et al. (2010) Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency. J Clin Endocrinol Metab 95: 1463–8

    Article  PubMed  CAS  Google Scholar 

  31. Ouchi N, Kihara S, Arita Y et al. (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100: 2473–6

    Article  PubMed  CAS  Google Scholar 

  32. Ouchi N, Kihara S, Arita Y et al. (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103: 1057–63

    Article  PubMed  CAS  Google Scholar 

  33. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105: 2893–8

    Google Scholar 

  34. Ouedraogo R, Wu X, Xu SQ et al. (2006) Adiponectin suppression of high-glucoseinduced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 55:1840–6

    Article  Google Scholar 

  35. Lautamaki R, Ronnemaa T, Huupponen R et al. (2007) Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 56:881–6

    Article  PubMed  Google Scholar 

  36. Goldstein BJ, Scalia RG, Ma XL. (2009) Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 6: 27–35

    Article  PubMed  CAS  Google Scholar 

  37. Ouedraogo R, Gong Y, Berzins B et al. (2007) Adiponectin deficiency increases leukocyteendothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 117: 1718–26

    Article  PubMed  CAS  Google Scholar 

  38. Komai N, Morita Y, Sakuta T et al. (2007) Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 17: 385–90

    Article  PubMed  CAS  Google Scholar 

  39. Komaba H, Igaki N, Goto S et al. (2006) Increased serum high-molecular-weight complex of adiponectin in type 2 diabetic patients with impaired renal function. Am J Nephrol 26: 476–82

    Article  PubMed  CAS  Google Scholar 

  40. Lenghel AR, Kacso IM, Bondor CI et al. (2012) Intercellular adhesion molecule, plasma adiponectin and albuminuria in type 2 diabetic patients. Diabetes Res Clin Pract 95: 55–61

    Article  PubMed  CAS  Google Scholar 

  41. Sharma K, Ramachandrarao S, Qiu G et al. (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118: 1645–56

    PubMed  CAS  Google Scholar 

  42. Pistrosch F, Herbrig K, Kindel B et al. (2005) Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes, 54: 2206–11

    Article  PubMed  CAS  Google Scholar 

  43. Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA (2007) Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 72: 1367–73

    Article  PubMed  CAS  Google Scholar 

  44. Stenvinkel P (2011) Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. J Ren Nutr 21: 82–6

    Article  PubMed  CAS  Google Scholar 

  45. Menon V, Li L, Wang X et al. (2006) Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17: 2599–606

    Article  PubMed  CAS  Google Scholar 

  46. Jorsal A, Tarnow L, Frystyk J et al. (2008) Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 74: 649–54

    Article  PubMed  CAS  Google Scholar 

  47. Tentolouris N, Doulgerakis D, Moyssakis I et al. (2004) Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease. Horm Metab Res 36: 721–7

    Article  PubMed  CAS  Google Scholar 

  48. Komura N, Kihara S, Sonoda M et al. (2010) Increment and impairment of adiponectin in renal failure. Cardiovasc Res 86: 471–7

    Article  PubMed  CAS  Google Scholar 

  49. Ohashi N, Kato A, Misaki T et al. (2008) Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Internal Med 47: 485–91

    Article  Google Scholar 

  50. Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I et al. (2007) Total and highmolecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 92: 1041–8

    Article  PubMed  Google Scholar 

  51. Wang Y, Lam JB, Lam KS, Liu J et al. (2006) Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66: 11462–70.

    Article  PubMed  CAS  Google Scholar 

  52. Dal Maso L, Augustin LS, Karalis A et al. (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89: 1160–3

    Article  Google Scholar 

  53. Cust AE, Kaaks R, Friedenreich C et al. (2007) Plasma adiponectin levels and endometrial cancer risk in pre-and postmenopausal women. J Clin Endocrinol Metab 92: 255–63

    Article  PubMed  CAS  Google Scholar 

  54. Wei EK, Giovannucci E, Fuchs CS et al. (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97: 1688–94

    Article  PubMed  CAS  Google Scholar 

  55. Guadagni F, Roselli M, Martini F et al. (2009) Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res 29: 3321–7

    PubMed  CAS  Google Scholar 

  56. Kaklamani VG, Wisinski KB, Sadim M et al. (2008) Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA 300: 1523–31

    Article  PubMed  CAS  Google Scholar 

  57. Michalakis K, Williams CJ, Mitsiades N et al. (2007) Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 16: 308–13

    Article  PubMed  CAS  Google Scholar 

  58. Goktas S, Yilmaz MI, Caglar K et al. (2005) Prostate cancer and adiponectin. Urology 65: 1168–72

    Article  PubMed  Google Scholar 

  59. Ishikawa M, Kitayama J, Kazama S et al. (2005) Plasma adiponectin and gastric cancer. Clin Cancer Res 11(2 Pt 1): 466–72

    PubMed  CAS  Google Scholar 

  60. Spyridopoulos TN, Petridou ET, Skalkidou A et al. (2007) Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 120: 1573–8

    Article  PubMed  CAS  Google Scholar 

  61. Avcu F, Ural AU, Yilmaz MI et al. (2006) Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases. Int J Hematol 83: 254–8

    Article  PubMed  Google Scholar 

  62. Petridou E, Mantzoros CS, Dessypris N et al. (2006) Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 94: 156–60

    Article  PubMed  CAS  Google Scholar 

  63. Lang K, Ratke J. (2009) Leptin and Adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal 7:27

    Article  PubMed  Google Scholar 

  64. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS (2007) Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 86: s858–66

    Google Scholar 

  65. Bröakenhielm E, Veitonmäki N, Cao R et al. (2004) Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci États-Unis 101: 2476–81

    Article  Google Scholar 

  66. Chiu YC, Shieh DC, Tong KM et al. (2009) Involvement of AdipoR receptor in adiponectin-induced motility and alpha2beta1 integrin upregulation in human chondrosarcoma cells. Carcinogenesis 30: 1651–9

    Article  PubMed  CAS  Google Scholar 

  67. Luo Z, Saha AK, Xiang X, Ruderman NB (2005) AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26: 69–76

    Article  PubMed  CAS  Google Scholar 

  68. Dieudonne MN, Bussiere M, Dos Santos E et al. (2006) Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345: 271–9

    Article  PubMed  CAS  Google Scholar 

  69. Wang Y, Lam KS, Xu JY, Lu G et al. (2005) Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280:8341–7

    Google Scholar 

  70. Lenchik L, Register TC, Hsu FC et al. (2003) Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 33: 646–51

    Article  PubMed  CAS  Google Scholar 

  71. Peng XD, Xie H, Zhao Q et al. (2008) Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 387: 31–5

    Article  PubMed  CAS  Google Scholar 

  72. Ealey KN, Kaludjerovic J, Archer MC, Ward WE (2008) Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp Biol Med (Maywood) 233:1546–53

    Article  CAS  Google Scholar 

  73. Okuno S, Ishimura E, Norimine K et al. (2011) Serum adiponectin and bone mineral density in male hemodialysis patients. Osteoporos Int (Epub ahead of print)

    Google Scholar 

  74. Sood A (2010) Obesity, adipokines, and lung disease. J Appl Physiol 108: 744–53

    Article  PubMed  CAS  Google Scholar 

  75. Shore SA (2008) Obesity and asthma: possible mechanisms. J Allergy Clin Immunol 121:1087–93

    Article  PubMed  Google Scholar 

  76. Sood A, Cui X, Qualls C et al. (2008) Association between asthma and serum adiponectin concentration in women. Thorax 63: 877–82

    Article  PubMed  CAS  Google Scholar 

  77. Silva FM, de Almeida JC, Feoli AM (2011) Effect of diet on adiponectin levels in blood. Nutr Rev 69: 599–612

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut des maladies cardiométaboliques et de la nutrition (IHU ICAN) et Service de Biochimie et Hormonologie, Hôpital Tenon, 4 rue de la Chine, 75970, Paris Cedex 20, France

    J.-P. Bastard

  2. CDR Saint-Antoine INSERM UMRS 938, Faculté de Médecine et Université Pierre et Marie Curie, site Saint-Antoine, 27 rue Chaligny, Paris, 75012

    J.-P. Bastard, C. Vatier & B. Fève

  3. Service d’Endocrinologie-Métabolisme, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012, Paris, France

    B. Fève

Authors
  1. J.-P. Bastard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Vatier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Fève
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J.-P. Bastard .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Paris

About this chapter

Cite this chapter

Bastard, JP., Vatier, C., Fève, B. (2013). L’adiponectine : une adipokine aux multiples visages. In: Physiologie et physiopathologie du tissu adipeux. Springer, Paris. https://doi.org/10.1007/978-2-8178-0332-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0332-6_13

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0331-9

  • Online ISBN: 978-2-8178-0332-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation